Cargando…
Ranibizumab versus Bevacizumab for Ophthalmic Diseases Related to Neovascularisation: A Meta-Analysis of Randomised Controlled Trials
BACKGROUND: Bevacizumab is believed to be as effective and safe as ranibizumab for ophthalmic diseases; however, its magnitude of effectiveness and safety profile remain controversial. Thus, a meta-analysis and systematic review appears necessary. METHODS: PubMed and EMBASE were systematically searc...
Autores principales: | Wu, Bin, Wu, Haixiang, Liu, Xiaoyan, Lin, Houwen, Li, Jin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4077727/ https://www.ncbi.nlm.nih.gov/pubmed/24983855 http://dx.doi.org/10.1371/journal.pone.0101253 |
Ejemplares similares
-
A systematic review and meta-analysis comparing intravitreal ranibizumab with bevacizumab for the treatment of myopic choroidal neovascularisation
por: Loutfi, M., et al.
Publicado: (2015) -
Effect of Intravitreal Ranibizumab in the Treatment of Peripapillary Choroidal Neovascularisation
por: Hamoudi, Hassan, et al.
Publicado: (2011) -
Bevacizumab and ranibizumab for neovascular age-related macular degeneration: an updated meta-analysis of randomised clinical trials
por: Kodjikian, Laurent, et al.
Publicado: (2014) -
A Safety Review and Meta-Analyses of Bevacizumab and Ranibizumab: Off-Label versus Goldstandard
por: Schmucker, Christine, et al.
Publicado: (2012) -
Lasting Controversy on Ranibizumab and Bevacizumab
por: Zou, Lihui, et al.
Publicado: (2011)